Cargando…
Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
Next-generation sequencing (NGS) has been applied to monitor minimal residual disease (MRD) in multiple myeloma (MM). Standardized DNA input and sequencing depth is essential for achieving a uniform sensitivity in NGS-based MRD study. Herein, the sensitivity of 10(−5) was verified by a standardized...
Autores principales: | Yao, Qiumei, Bai, Yinlei, Orfao, Alberto, Chim, Chor Sang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563351/ https://www.ncbi.nlm.nih.gov/pubmed/31245284 http://dx.doi.org/10.3389/fonc.2019.00449 |
Ejemplares similares
-
Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR
por: Yao, Qiumei, et al.
Publicado: (2021) -
High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes
por: Bai, Yinlei, et al.
Publicado: (2016) -
Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023) -
“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022) -
Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)